JFJoshua R. Friedman

Joshua R. Friedman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joshua R. Friedman has a total of 404 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A temporal classifier predicts histopathology state and parses acute-chronic phasing in inflammatory bowel disease patients

    by Lauren A. Peters, Joshua R. Friedman, Aleksandar Stojmirovic, Jacob Hagen, Sander Houten, Tetyana Dodatko, Mariana P. Amaro, Paula Restrepo, Zhi Chai, J. Rodrigo Mora, et al.

    Previous studies have conducted time course characterization of murine colitis models through transcriptional profiling of differential expression. We characterize the transcriptional landscape of acute and chronic models of dextran sodium sulfate (DSS) and adoptive transfer (AT) colitis to derive temporal gene expression and splicing signatures in blood and colonic tissue in order to capture dynamics of colitis remission and relapse. We identify sub networks of patient-derived causal networks that are enriched in these temporal signatures to distinguish acute and chronic disease components within the broader molecular landscape of IBD. The interaction between the DSS phenotype and chronological time-point naturally defines parsimonious temporal gene expression and splicing signatures associated with acute and chronic phases disease (as opposed to ordinary time-specific differential expression/splicing). We show these expression and splicing signatures are largely orthogonal, i.e. affect different genetic bodies, and that using machine learning, signatures are predictive of histopathological measures from both blood and intestinal data in murine colitis models as well as an independent cohort of IBD patients. Through access to longitudinal multi-scale profiling from disease tissue in IBD patient cohorts, we can apply this machine learning pipeline to generation of direct patient temporal multimodal regulatory signatures for prediction of histopathological outcomes.


  • Open Access

    Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy

    by Polychronis Pavlidis, Anastasia Tsakmaki, Eirini Pantazi, Katherine Li, Domenico Cozzetto, Jonathan Digby- Bell, Feifei Yang, Jonathan W. Lo, Elena Alberts, Ana Caroline Costa Sa, et al.

    The function of interleukin-22 (IL-22) in intestinal barrier homeostasis remains controversial. Here, we map the transcriptional landscape regulated by IL-22 in human colonic epithelial organoids and evaluate the biological, functional and clinical significance of the IL-22 mediated pathways in ulcerative colitis (UC). We show that IL-22 regulated pro-inflammatory pathways are involved in microbial recognition, cancer and immune cell chemotaxis; most prominently those involving CXCR2+ neutrophils. IL-22-mediated transcriptional regulation of CXC-family neutrophil-active chemokine expression is highly conserved across species, is dependent on STAT3 signaling, and is functionally and pathologically important in the recruitment of CXCR2+ neutrophils into colonic tissue. In UC patients, the magnitude of enrichment of the IL-22 regulated transcripts in colonic biopsies correlates with colonic neutrophil infiltration and is enriched in non-responders to ustekinumab therapy. Our data provide further insights into the biology of IL-22 in human disease and highlight its function in the regulation of pathogenic immune pathways, including neutrophil chemotaxis. The transcriptional networks regulated by IL-22 are functionally and clinically important in UC, impacting patient trajectories and responsiveness to biological intervention.


  • O32 The interleukin 22//neutrophil axis is associated with treatment resistance in ulcerative colitis

    by Polychronis Pavlidis, Anastasia Tsakmaki, Eirini Pantazi, Katherine Li, Domenico Cozzetto, Feifei Yang, Jonathan Lo, Elena Alberts, Ana Caroline Costa Sa, Umar Niazi, et al.

    Introduction Interleukin (IL) 22 is a key cytokine involved in regulation of epithelial function and its role in IBD remains highly controversial. Some studies indicate a protective role in epithelial regeneration, whereas other studies imply a pro-inflammatory role. Insights are now needed to improve of understanding of the functional role of this important cytokine and how its expression might impact patients with ulcerative colitis (UC). In this study, we have probed the clinical and functional significance of IL-22 responsive transcriptional modules and causal networks in diseased tissue of over 500 UC patients and in preclinical models of colitis. Methods We mapped the transcriptional landscape of human colonic epithelial 3D mini-gut organoids in response to treatment with IL22, and other pro-inflammatory cytokines. We tested the clinical significance of the IL22-regulated transcriptome by probing whole colonic biopsies from 550 ulcerative colitis (UC) patients from UNIFI clinical trial programme (patients with UC treated with ustekinumab, an anti-IL12p40 antibody). The functional role of IL22 regulated biological pathways were evaluated in pre-clinical models of UC. Results IL-22 regulated pro-inflammatory biological pathways involved in microbial recognition, cancer and immune cell chemotaxis. IL-22 was an especially potent regulator of the CXC family chemokines CXCL1, CXCL2, CXCL5, CXCL6 and CXCL8, which are all powerful neutrophil-selective chemokines. There was a positive correlation between the IL-22 transcriptional programme and the histological severity of inflammation (r=0.49, p+ neutrophils to the colon. Conclusions The interleukin 22/neutrophil axis is functionally important in colitis and is associated with treatment resistance in ulcerative colitis

  • 103: MACHINE LEARNING IDENTIFIES A 14 GENE TRANSCRIPTIONAL SIGNATURE IN THE CYTOKINE-REGULATED TRANSCRIPTOME THAT PREDICTS RESPONSE TO USTEKINUMAB IN CROHN'S DISEASE

    by Polychronis Pavlidis, Feifei Yang, Anastasia Tsakmaki, Domenico Cozzetto, Umar Niazi, Mansoor Saqi, Joshua Friedman, Gavin Bewick, Katherine Li, Nick Powell

  • Open Access

    Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells

    by Nick Powell, Eirini Pantazi, Polychronis Pavlidis, Anastasia Tsakmaki, Katherine Li, Feifei Yang, Aimee Parker, Carmen Pin, Domenico Cozzetto, Danielle Minns, et al.

    Objective The functional role of interleukin-22 (IL22) in chronic inflammation is controversial, and mechanistic insights into how it regulates target tissue are lacking. In this study, we evaluated the functional role of IL22 in chronic colitis and probed mechanisms of IL22-mediated regulation of colonic epithelial cells. Design To investigate the functional role of IL22 in chronic colitis and how it regulates colonic epithelial cells, we employed a three-dimentional mini-gut epithelial organoid system, in vivo disease models and transcriptomic datasets in human IBD. Results As well as inducing transcriptional modules implicated in antimicrobial responses, IL22 also coordinated an endoplasmic reticulum (ER) stress response transcriptional programme in colonic epithelial cells. In the colon of patients with active colonic Crohn’s disease (CD), there was enrichment of IL22-responsive transcriptional modules and ER stress response modules. Strikingly, in an IL22-dependent model of chronic colitis, targeting IL22 alleviated colonic epithelial ER stress and attenuated colitis. Pharmacological modulation of the ER stress response similarly impacted the severity of colitis. In patients with colonic CD, antibody blockade of IL12p40, which simultaneously blocks IL12 and IL23, the key upstream regulator of IL22 production, alleviated the colonic epithelial ER stress response. Conclusions Our data challenge perceptions of IL22 as a predominantly beneficial cytokine in IBD and provide novel insights into the molecular mechanisms of IL22-mediated pathogenicity in chronic colitis. Targeting IL22-regulated pathways and alleviating colonic epithelial ER stress may represent promising therapeutic strategies in patients with colitis. Trial registration number NCT02749630.


  • Open Access

    A negative role for the interleukin-2-inducible T-cell kinase (ITK) in human Foxp3+ TREG differentiation

    by Polina Mamontov, Ryan A Eberwine, Jackie Perrigoue, Anuk Das, Joshua R Friedman, J Rodrigo Mora

    The Tec kinases ITK (interleukin-2-inducible T-cell kinase) and RLK (resting lymphocyte kinase) are critical components of the proximal TCR/CD3 signal transduction machinery, and data in mice suggest that ITK negatively modulates regulatory T cell (TREG) differentiation. However, whether Tec kinases modulate TREG development and/or function in human T cells remains unknown. Using a novel self-delivery siRNA platform (sdRNA), we found that ITK knockdown in human primary naïve peripheral blood CD4 T cells increased Foxp3+ expression under both TREG and T helper priming conditions. TREG differentiated under ITK knockdown conditions exhibited enhanced expression of the co-inhibitory receptor PD-1 and were suppressive in a T cell proliferation assay. ITK knockdown decreased IL-17A production in T cells primed under Th17 conditions and promoted Th1 differentiation. Lastly, a dual ITK/RLK Tec kinase inhibitor did not induce Foxp3 in CD4 T cells, but conversely abrogated Foxp3 expression induced by ITK knockdown. Our data suggest that targeting ITK in human T cells may be an effective approach to boost TREG in the context of autoimmune diseases, but concomitant inhibition of other Tec family kinases may negate this effect.


  • Open Access

    A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials

    by Katherine Li, Richard Strauss, Colleen Marano, Linda E Greenbaum, Joshua R Friedman, Laurent Peyrin-Biroulet, Carrie Brodmerkel, Gert De Hertogh

    Histologic evaluation is a meaningful complement to endoscopic and clinical measures in ulcerative colitis [UC]. There is a need for a definition of histologic improvement that can be used in clinical trials, and any such definition must be predictive of disease outcomes. Biopsies were collected from clinical trials (PURSUIT-SC [n = 98], JAK-UC [n = 219], and PROgECT [n = 103]) in patients with moderate-to-severe UC. A pathologist assessed biopsies in a blinded fashion using the Geboes score. A dichotomous histologic improvement end point was defined by selecting Geboes score elements according to their association strength with endoscopic healing. Fisher’s exact test and Cramer’s V assessed the association of histology with other measures. Using PURSUIT-SC biopsies, histologic improvement was defined as absence of erosion or ulceration, absence of crypt destruction, and 90% of those with endoscopic healing in JAK-UC [Week 8] and PROgECT [Week 30] achieved histologic improvement. In JAK-UC, patients with histologic improvement had lower disease activity than patients without histologic improvement’ [Mayo score = 3.8 vs 7.5] at Week 8. Week 4 histologic improvement was a strong indicator of histologic improvement, endoscopic healing, and clinical response or remission at Week 8 [all p < 0.005]. In PROgECT, 73% of patients with histologic improvement at Week 6 achieved histologic improvement at Week 30 [p = 0.0013]. Histologic improvement based on a simplified, dichotomous Geboes score is associated with favourable endoscopic and clinical outcomes across multiple clinical studies and two therapeutic mechanisms of action. ClinicalTrials.gov number: NCT00487539 [PURSUIT-SC]; NCT01959282 [JAK-UC]; NCT01988961 [PROgECT].


  • Open Access

    OP17 A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies

    by R Huang, H Irizar, R Kosoy, W-M Song, A Dinarzo, K Hao, J Rogers, A Atreja, M Mahajan, A Stojmirovic, et al.

    Endoscopy, histology, and biomarker measures of inflammation have limitations of sensitivity, specificity, reproducibility, and range in evaluating inflammatory bowel disease (IBD). We explored whole transcriptome gene expression to define molecular scores of gut inflammation. These scores are applicable to both Crohn’s disease (CD) and ulcerative colitis (UC), enabling more granular, continuous measures across multiple states and location of disease. We present a molecular characterisation of IBD based on the transcription profiles of 719 endoscopically defined inflamed (Inf) and 1776 non-inflamed (NInf) intestinal biopsies from 498 CD, 419 UC patients in the Mount Sinai Crohn’s and Colitis Registry (MSCCR) during endoscopy. Genes differentially expressed between Inf and NInf biopsies were used to generate a biopsy-level molecular inflammation score (MIS) via gene set variation analysis.1 MIS was strongly associated with histological biopsy scores for CD (GHAS2) and UC (Nancy Index3) and independent of inflammatory status (Inf B = 3.1, NInf B = 2.73; p > 0.05) (Figure 1A), MIS of Inf biopsies was higher than NInf within the same histological score, indicating that MIS describes a broader range of inflammation signal than histologic assessment. MIS was also associated with endoscopically defined severity (SES-CD and Mayo-endo for UC); capturing the gradient from mild, moderate, to severe disease (Figure 1B). Association of MIS with clinical disease severity was significant for Inf biopsies for continuous measures (HBI for CD B = 0.65, p < 0.01; SCCAI for UC B = 1.94, p < 0.01) and could also differentiate between HBI and SCCAI defined active and inactive subsets (UC d = 11.5, p < 0.01; CD d = 5, p < 0.01). This was not the case for NInf biopsies (Figure 1C), indicating that the clinical scores track with inflammation but not with homeostatic features of the gut. Abstract OP017 Association of MIS with histological (A), endoscopic (B) and clinical (C) IBD severity. Means (black dots) and CI (blue) Abstract OP017 Association of MIS with histological (A), endoscopic (B) and clinical (C) IBD severity. Means (black dots) and CI (blue) We generated a transcriptionally based intestinal inflammation score in IBD patients, which provides an objective quantification of disease state in IBD-relevant tissues. MIS scores are associated with features captured by histological, endoscopic, and clinical evaluations, but do so with a greater dynamic range, and as a common metric for CD and UC. Further work will explore whether MIS may improve patients subsetting, identify sub-clinical disease, predict flares or therapeutic response. Furthermore, MIS can be used to regress the inflammation component, revealing novel non-inflammatory mechanisms. References 1. Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14:7. 2. D’Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262–7. 3. Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of the Nancy histological index for UC. Gut, 2017;66:43–9.


  • Open Access

    Gut microbiota density influences host physiology and is shaped by host and microbial factors

    by Eduardo J Contijoch, Graham J Britton, Chao Yang, Ilaria Mogno, Zhihua Li, Ruby Ng, Sean R Llewellyn, Sheela Hira, Crystal Johnson, Keren M Rabinowitz, et al.

    To identify factors that regulate gut microbiota density and the impact of varied microbiota density on health, we assayed this fundamental ecosystem property in fecal samples across mammals, human disease, and therapeutic interventions. Physiologic features of the host (carrying capacity) and the fitness of the gut microbiota shape microbiota density. Therapeutic manipulation of microbiota density in mice altered host metabolic and immune homeostasis. In humans, gut microbiota density was reduced in Crohn’s disease, ulcerative colitis, and ileal pouch-anal anastomosis. The gut microbiota in recurrent Clostridium difficile infection had lower density and reduced fitness that were restored by fecal microbiota transplantation. Understanding the interplay between microbiota and disease in terms of microbiota density, host carrying capacity, and microbiota fitness provide new insights into microbiome structure and microbiome targeted therapeutics.


  • Open Access

    Low-Dose Interleukin-2 Ameliorates Colitis in a Preclinical Humanized Mouse Model

    by Jeremy A. Goettel, Daniel Kotlarz, Rohini Emani, James B. Canavan, Liza Konnikova, David Illig, Sandra M. Frei, Michael Field, Matthew Kowalik, Kaiyue Peng, et al.